Dilli Poudel1, Michael D George1,2, Joshua F Baker3,4,5,6. 1. Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA. 3. Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA. Joshua.Baker@pennmedicine.upenn.edu. 4. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA. Joshua.Baker@pennmedicine.upenn.edu. 5. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. Joshua.Baker@pennmedicine.upenn.edu. 6. Division of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, 5 White Building, 3400 Spruce Street, Philadelphia, PA, 19104, USA. Joshua.Baker@pennmedicine.upenn.edu.
Abstract
PURPOSE OF THE REVIEW: A growing number of studies have suggested that disease outcomes and response to therapy may be different in patients with rheumatoid arthritis (RA) who are obese. The goal of this review is to examine the most recent literature, with a focus on the impact of obesity on the assessment of disease activity and treatment outcomes in RA. RECENT FINDINGS: Obesity is common in patients with RA and can have a substantial impact on patient symptoms and outcomes. Obesity is associated with higher rates of chronic pain and opiate use, elevated inflammatory markers, and less reliable physical exam findings, making assessment of disease activity and treatment response more challenging. Despite seemingly worse clinical disease activity, evidence has accumulated demonstrating that obese patients with RA have less inflammation by imaging and lower rates of radiographic progression over time. Whether obesity influences the effectiveness of specific therapies remains controversial. Obesity is very common and is associated with more severe symptoms and higher rates of disability among RA patients. While clinical disease activity is frequently observed to be higher in obese patients with RA, it remains unclear whether poorer treatment response rates in this setting are related to reduced efficacy of therapies or are an artifact of biases in the accurate assessment of the disease.
PURPOSE OF THE REVIEW: A growing number of studies have suggested that disease outcomes and response to therapy may be different in patients with rheumatoid arthritis (RA) who are obese. The goal of this review is to examine the most recent literature, with a focus on the impact of obesity on the assessment of disease activity and treatment outcomes in RA. RECENT FINDINGS:Obesity is common in patients with RA and can have a substantial impact on patient symptoms and outcomes. Obesity is associated with higher rates of chronic pain and opiate use, elevated inflammatory markers, and less reliable physical exam findings, making assessment of disease activity and treatment response more challenging. Despite seemingly worse clinical disease activity, evidence has accumulated demonstrating that obesepatients with RA have less inflammation by imaging and lower rates of radiographic progression over time. Whether obesity influences the effectiveness of specific therapies remains controversial. Obesity is very common and is associated with more severe symptoms and higher rates of disability among RApatients. While clinical disease activity is frequently observed to be higher in obesepatients with RA, it remains unclear whether poorer treatment response rates in this setting are related to reduced efficacy of therapies or are an artifact of biases in the accurate assessment of the disease.
Entities:
Keywords:
Adiposity; Body mass index; Obesity; Rheumatoid arthritis
Authors: A Chiricozzi; A Zangrilli; M Bavetta; L Bianchi; S Chimenti; R Saraceno Journal: J Eur Acad Dermatol Venereol Date: 2016-06-21 Impact factor: 6.166
Authors: N Cassano; F Loconsole; A Galluccio; A Miracapillo; M Pezza; G A Vena Journal: Int J Immunopathol Pharmacol Date: 2006 Jan-Mar Impact factor: 3.219
Authors: Michael D George; Jon T Giles; Patricia P Katz; Bryant R England; Ted R Mikuls; Kaleb Michaud; Alexis R Ogdie-Beatty; Said Ibrahim; Grant W Cannon; Liron Caplan; Brian C Sauer; Joshua F Baker Journal: Arthritis Care Res (Hoboken) Date: 2017-11-06 Impact factor: 4.794
Authors: Michael D George; Brian C Sauer; Chia-Chen Teng; Grant W Cannon; Bryant R England; Gail S Kerr; Ted R Mikuls; Joshua F Baker Journal: J Rheumatol Date: 2018-10-01 Impact factor: 4.666
Authors: Iain M Carey; Julia A Critchley; Stephen DeWilde; Tess Harris; Fay J Hosking; Derek G Cook Journal: Diabetes Care Date: 2018-01-12 Impact factor: 19.112
Authors: Kacper A Wojtal; Gerhard Rogler; Michael Scharl; Luc Biedermann; Pascal Frei; Michael Fried; Achim Weber; Jyrki J Eloranta; Gerd A Kullak-Ublick; Stephan R Vavricka Journal: PLoS One Date: 2012-08-24 Impact factor: 3.240
Authors: Joshua F Baker; Mikkel Ostergaard; Michael George; Justine Shults; Paul Emery; Daniel G Baker; Philip G Conaghan Journal: Ann Rheum Dis Date: 2014-08-04 Impact factor: 19.103
Authors: Ulf Müller-Ladner; Klaus Frommer; Thomas Karrasch; Elena Neumann; Andreas Schäffler Journal: Z Rheumatol Date: 2021-03-27 Impact factor: 1.372
Authors: Sandra Haider; Michael Sedlak; Ali Kapan; Igor Grabovac; Thomas Lamprecht; Ludwig Erlacher; Michael Quittan; Karl Heinrich Fenzl; Thomas Ernst Dorner Journal: Int J Environ Res Public Health Date: 2020-12-03 Impact factor: 3.390